Search

Your search keyword '"Bourdin, Arnaud"' showing total 1,156 results

Search Constraints

Start Over You searched for: Author "Bourdin, Arnaud" Remove constraint Author: "Bourdin, Arnaud" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
1,156 results on '"Bourdin, Arnaud"'

Search Results

1. Development and external validation of a prediction model for the transition from mild to moderate or severe form of COVID-19

2. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects.

5. CT Imaging Assessment of Response to Treatment in Allergic Bronchopulmonary Aspergillosis in Adults With Bronchial Asthma

6. Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma

10. Anti–IL-4R versus anti–IL-5/5R after anti–IL-5/5R failure in asthma: An emulated target trial

11. Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry

13. Global access and patient safety in the transition to environmentally friendly respiratory inhalers: the Global Initiative for Asthma perspective

15. Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry

18. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis – 2021 update. Full-length version

19. Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy

20. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study

21. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial

22. Anti-IL-4R versus Anti-IL-5/5R after Anti-IL-5/5R failure in asthma: an emulated target trial

23. VJBM-2023-0014 Final

25. Altered skeletal muscle function and beneficial effects of exercise training in a rat model of induced pulmonary emphysema

29. Serum and Pulmonary Expression Profiles of the Activin Signaling System in Pulmonary Arterial Hypertension

30. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases

31. Position paper of the French Society of Respiratory Diseases regarding pharmacological treatment optimization for stable COPD in 2021

32. Non-typeable Haemophilus influenzae–Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial

33. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

34. iPSCs derived from infertile men carrying complex genetic abnormalities can generate primordial germ-like cells

37. CRISPR/Cas9-mediated gene knockout and interallelic gene conversion in human induced pluripotent stem cells using non-integrative bacteriophage-chimeric retrovirus-like particles

39. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial

40. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study

42. The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease

44. Trends in Systemic Glucocorticoid Utilization in the United Kingdom from 1990 to 2019: A Population-Based, Serial Cross-Sectional Analysis

45. Severe asthma care trajectories: the French RAMSES cohort

46. Evaluating the Effect of Dupilumab on Type 2 Airway Inflammation and Mucus Plugging in Patients with Uncontrolled Moderate-To-Severe Asthma: the VESTIGE Trial

47. Longitudinal patterns of intermittent oral corticosteroid use for asthma in the UK

48. Reply to “Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry”

49. Long-Term Efficacy Of Dupilumab In Patients With Moderate-To-Severe Type 2 Asthma Stratified By Baseline Characteristics During The 96-Week TRAVERSE Study

50. Efficacy and Safety of Benralizumab Compared with Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Patients Receiving Standard of Care Therapy: Phase 3 MANDARA Study

Catalog

Books, media, physical & digital resources